Alkermes Plc 's Revenue in the fiscal year 2025 $ 1,475.90 millions
Alkermes Plc 's Revenue in the fiscal year 2024 $ 1,557.63 millions
Alkermes Plc 's Revenue in the fiscal year 2023 $ 1,663.41 millions
Alkermes Plc 's Revenue in the fiscal year 2022 $ 1,111.80 millions
Alkermes Plc 's Revenue in the fiscal year 2021 $ 1,173.75 millions
ALKS Revenue third quarter 2026 Y/Y Growth Comment
Alkermes Plc achieved in the third quarter 2026, above Company average Revenue growth of 21.8% year on year, to $ 480.13 millions.
Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 77 other companies have achieved higher Revenue growth. While Alkermes Plc ' s Revenue rise of 21.8% ranks overall at the positon no. 808 in the third quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Alkermes Plc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
114.68 %
3.97 %
-100 %
(Jun 30 2023)
ALKS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Alkermes Plc disclosed fall in Revenue from the second quarter by -3.2% to $ 480.13 millions, from $ 496.01 millions achived in the previous reporting period.
Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.
Within Major Pharmaceutical Preparations industry 42 other companies have achieved higher Revenue quarter on quarter growth. While Alkermes Plc 's Revenue growth quarter on quarter, overall rank is 399.
In the III. Quarter 2026 Alkermes Plc disclosed fall in Revenue from the second quarter by -3.2% to $ 480.13 millions, from $ 496.01 millions achived in the previous reporting period.
Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.
Within Major Pharmaceutical Preparations industry 42 other companies have achieved higher Revenue quarter on quarter growth. While Alkermes Plc 's Revenue growth quarter on quarter, overall rank is 399.
Alkermes Plc 's 12 Months Revenue Growth Year on Year
Alkermes Plc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 15.27% year on year, to $ 1,754 millions if the fiscal year would have ended in Sep 30 2026. Alkermes Plc 's trailing twelve months Revenue growth was higher than company's average 9.3% and higher than 10.79% growth in Jun 30 2026. But from twelve months ended Jun 30 2026 rise was beneth at 5.15 % from $1667.65 millions achieved in the period from Jun 30 2026 to Sep 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at9.3%.
In the Healthcare sector 365 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2510, from total ranking in previous quarter at 3083.
Alkermes Plc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 15.27% year on year, to $ 1,754 millions if the fiscal year would have ended in Sep 30 2026. Alkermes Plc 's trailing twelve months Revenue growth was higher than company's average 9.3% and higher than 10.79% growth in Jun 30 2026. But from twelve months ended Jun 30 2026 rise was beneth at 5.15 % from $1667.65 millions achieved in the period from Jun 30 2026 to Sep 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at9.3%. The momentum is even more impressive from twelve months ended Jun 30 2026 exhibited at 5.15 % increase from $1667.65 millions in the period from Jun 30 2026 to Sep 30 2025.
In the Healthcare sector 365 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2510, from total ranking in previous quarter at 3083.
About Alkermes Plc Revenue Growth Rates (ALKS), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
37.42%